Retatrutide and Bowel Changes: What Trial Data Show

Retatrutide makes me poop is a concern reported by some participants in clinical trials of this investigational triple receptor agonist, which targets GLP-1, GIP and glucagon receptors simultaneously. Because these receptors are involved in gut motility, gastric emptying and bile acid metabolism, gastrointestinal effects including diarrhoea, loose stools and altered bowel habits have been among the most commonly reported findings in trial data. Retatrutide holds no marketing authorisation in the UK or elsewhere, and all information about its effects comes from authorised clinical trials.

Why does retatrutide affect your bowels?

Retatrutide activates GLP-1, GIP and glucagon receptors in the gut, altering gastric emptying, intestinal motility and bile acid metabolism, which can cause diarrhoea, loose stools or constipation depending on the individual.

Retatrutide affects the bowels primarily because it acts on hormone receptors in the gut that regulate digestion, gastric emptying and intestinal motility. Retatrutide is a triple receptor agonist, meaning it activates three distinct receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This receptor profile was described in the Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023).

The GLP-1 component is particularly relevant to gut symptoms. GLP-1 receptor agonists are well established to slow gastric emptying, which means food moves more slowly from the stomach into the small intestine.^[4][5] This slowing can cause nausea, bloating and a sensation of fullness, but it can also alter the rhythm of bowel movements in ways that vary between individuals.

The glucagon receptor activity adds another layer of complexity. Glucagon is known to influence gut motility and has effects on bile acid metabolism; both of these can affect stool consistency and frequency. When these hormonal signals are amplified by a pharmacological agent, the gut's normal rhythm can be disrupted, leading some people to experience looser stools or more frequent bowel movements, while others may experience constipation.

It is important to note that retatrutide holds no marketing authorisation in the UK or anywhere else.^[14][15] All available information about its effects, including its gastrointestinal profile, comes from data reported in authorised clinical trials. The mechanisms described here are based on the known pharmacology of the receptor classes it targets, and individual responses observed in trial participants may not reflect what every person would experience.

What gut side effects have clinical trials reported?

The Phase 2 NEJM trial (Jastreboff et al., 2023) found nausea, diarrhoea, vomiting and constipation were the most common side effects, clustering around dose-escalation periods and generally mild to moderate in severity.

Clinical trial data for retatrutide have reported a range of gastrointestinal side effects, with nausea, diarrhoea, vomiting and constipation among the most commonly observed findings. The Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.), which enrolled adults with obesity over 48 weeks, found that gastrointestinal adverse events were the most frequently reported side effects across all dose groups.^[1] Diarrhoea and nausea were particularly common, especially during the dose-escalation period when participants were moving to higher doses.^[1][9]

The Phase 3 TRIUMPH and TRANSCEND trial programmes have since provided additional data in broader populations, including people with type 2 diabetes. Published and congress-reported findings from these programmes, including data presented at major diabetes and endocrinology meetings, indicate that the gastrointestinal side effect profile has remained broadly consistent with what was seen in Phase 2, with symptoms tending to cluster around dose increases rather than persisting at a steady rate throughout treatment. Readers seeking the primary data should refer to the named trial publications and congress abstracts directly, as the full Phase 3 dataset continues to be reported.

It is worth noting that the severity of gut symptoms varied considerably between participants. Most events were described as mild to moderate in intensity. Serious gastrointestinal adverse events were reported less frequently, though they did occur in some participants. As a class-level concern, acute pancreatitis has been reported with GLP-1 receptor agonist medicines; the UK SmPCs for related licensed medicines note that reports have included necrotising pancreatitis and cases with fatal outcomes, and no reliable risk magnitude has been established for the class. Whether pancreatitis has been reported specifically with retatrutide in Phase 2 or Phase 3 outputs has not been confirmed in publicly available data at the time of writing; the mention here reflects a class warning rather than a confirmed retatrutide-specific finding. These findings from named trials describe outcomes in specific trial populations under controlled conditions and should not be interpreted as a prediction of what any individual would experience.

How long do digestive symptoms usually last?

Trial data indicate gut symptoms are most prominent during dose escalation and tend to diminish once a stable dose is reached, though a proportion of participants continued to experience them throughout the study.

Based on data reported from retatrutide clinical trials, digestive symptoms have generally been most prominent during the dose-escalation phase of treatment and have tended to diminish once a stable dose is reached. This pattern is consistent with what has been observed with other GLP-1 receptor agonist medicines, where the gut appears to adapt over time to the altered hormonal signalling.

In the Phase 2 trial reported in the New England Journal of Medicine (Jastreboff et al., 2023), gastrointestinal events were most frequently reported in the earlier weeks of treatment. For many participants, symptoms such as nausea and diarrhoea reduced in frequency and intensity as the trial progressed, though a proportion of participants continued to experience them throughout. A small number of participants discontinued treatment due to gastrointestinal side effects.

Because retatrutide is not authorised in the UK and is available only within authorised clinical trials, there is no established clinical guidance on managing its side effects in routine practice. The duration of symptoms in any individual would depend on factors including the dose being studied, the rate of escalation used in the trial protocol, and individual variation in gut sensitivity. If you are a trial participant and are considering taking any over-the-counter remedy for symptoms such as diarrhoea or nausea, check with your trial team first, as some treatments may be restricted under the study protocol. Anyone participating in an authorised clinical trial who experiences persistent or worsening digestive symptoms should report these to the trial team under the study protocol, as adverse event reporting within a trial follows a specific process. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

When should you speak to a doctor about your symptoms?

Severe abdominal pain radiating to the back, signs of significant dehydration, or persistent diarrhoea lasting more than a few days all require prompt medical attention via A&E, NHS 111 or your GP.

Anyone experiencing severe, persistent or worsening gastrointestinal symptoms should seek medical advice promptly, and the appropriate route depends on the urgency of the situation. If you are a participant in an authorised clinical trial of retatrutide, your first point of contact for any symptoms should be the trial team, who are responsible for monitoring your safety under the study protocol.

For symptoms that are distressing but not immediately life-threatening, such as persistent diarrhoea lasting more than a few days, significant nausea that prevents eating or drinking, or unexplained abdominal pain, contact your GP. If your GP surgery is closed and you need urgent advice, NHS 111 can help direct you to the appropriate service.

Some symptoms warrant more urgent attention. Severe abdominal pain, particularly pain that radiates to the back and is accompanied by vomiting, can be a sign of pancreatitis, which requires prompt medical assessment. If you experience these symptoms, go to your nearest accident and emergency department or call 999 if you are unable to travel safely.

Signs of significant dehydration resulting from prolonged diarrhoea or vomiting, including dizziness, very dark urine, confusion or inability to keep fluids down, also require prompt assessment. Contact NHS 111 or your GP depending on severity.

If you are a trial participant and need emergency or urgent care, tell the clinicians treating you that you are enrolled in a clinical trial and that you are receiving an investigational medicine. Carry your trial participant card or documentation with you so that emergency clinicians can contact the trial team if needed.

It is always reasonable to discuss any new or troubling digestive symptoms with a healthcare professional, even if they seem minor, particularly in the context of any medicine or trial treatment that acts on the gut.

What is the regulatory status of retatrutide in the UK?

Retatrutide has no UK marketing authorisation and cannot be prescribed or supplied outside an authorised clinical trial; anything sold online as retatrutide is unlicensed and may be falsified or unsafe.

Retatrutide does not hold a marketing authorisation in the UK or in any other country, and no date can be given for when or whether it might receive one.^[14][15] In the UK, medicines are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Until the MHRA grants a marketing authorisation following a full review of safety, quality and efficacy data, retatrutide cannot be prescribed or supplied outside an authorised clinical trial. Under UK medicines legislation and MHRA guidance on the advertising and promotion of medicines, unlicensed medicines cannot be advertised to the public. Anything sold online or through any other channel as retatrutide is not a licensed product and may be falsified or unsafe.

The clinical evidence base for retatrutide comes from named trials, including the Phase 2 study published in the New England Journal of Medicine and the ongoing Phase 3 TRIUMPH and TRANSCEND programmes. These trials are conducted under strict regulatory oversight, and participants are enrolled according to defined eligibility criteria. Trial participants who are pregnant, breastfeeding or planning a pregnancy are excluded from participation, and contraception requirements apply within the trial setting.

For people who are interested in weight management treatments that are currently authorised in the UK, licensed options exist and can be discussed with a GP, who can advise on eligibility and appropriate pathways. Local commissioning decisions about NHS access to licensed weight-management medicines are made by Integrated Care Boards (ICBs), and availability may vary by area. Anyone who believes they have been offered retatrutide outside a clinical trial setting should report this to the MHRA, as it would represent a serious regulatory concern.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al.).
2. Cardiovascular Effects of Incretin Receptor Agonists: Beyond Glycemic Control.
3. Advances in the Management of Obesity: Non-pharmacological Strategies, Herbal Formulations, Current Pharmacotherapy, Emerging Drugs, and Future Perspectives.
4. Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists: A Narrative Expert Review of Approved Therapies, Oral Formulations, and Pipeline Agents.
5. Insights into Natural Dietary Components as Indirect Modulators of GLP-1 Receptor Signaling in Weight Management.
6. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Receptor Agonist Medications.
7. Effects of Chronic Glucagon Administration on Cholesterol Transformation into Bile Acids (Guettet et al.).
8. Bile Acid Receptors and Gastrointestinal Functions.
9. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: a Randomised, Double-blind, Phase 2 Trial.
10. Retatrutide in Adults with Obesity and Type 2 Diabetes (TRIUMPH-2): Phase 3 Trial (Bellido et al.).
11. Efficacy and Safety of Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, as Monotherapy in People with Type 2 Diabetes (Bajaj et al.).
12. GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: Strengthened Warnings on Acute Pancreatitis, Including Necrotising and Fatal Cases.
13. The Yellow Card Scheme: Guidance for Healthcare Professionals, Patients and the Public.
14. Advertise Your Medicines.
15. Mounjaro — European Public Assessment Report.

Frequently Asked Questions